Concerning the safety of the different treatment regimens, various studies have suggested that advanced age is a risk factor for the development of severe and opportunistic infections in IBD patients treated with corticoids, immunomodulators, and anti-TNF biologic agents [20,21,22,23,36]. Here, TNF is linked to inflammatory bowel disease.